Barclays PLC Raises Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Barclays PLC increased its stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 178.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,660,059 shares of the biotechnology company's stock after buying an additional 1,064,909 shares during the quarter. Barclays PLC owned 0.61% of Pacific Biosciences of California worth $3,038,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. PCA Investment Advisory Services Inc. boosted its holdings in Pacific Biosciences of California by 50.0% during the fourth quarter. PCA Investment Advisory Services Inc. now owns 15,000 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 5,000 shares during the last quarter. Impact Partnership Wealth LLC grew its holdings in shares of Pacific Biosciences of California by 29.5% in the fourth quarter. Impact Partnership Wealth LLC now owns 50,735 shares of the biotechnology company's stock valued at $93,000 after acquiring an additional 11,566 shares in the last quarter. Wealthfront Advisers LLC increased its position in shares of Pacific Biosciences of California by 50.8% during the fourth quarter. Wealthfront Advisers LLC now owns 62,648 shares of the biotechnology company's stock valued at $115,000 after acquiring an additional 21,092 shares during the last quarter. Sanctuary Advisors LLC lifted its holdings in Pacific Biosciences of California by 218.3% during the fourth quarter. Sanctuary Advisors LLC now owns 35,457 shares of the biotechnology company's stock worth $65,000 after acquiring an additional 24,318 shares during the period. Finally, FNY Investment Advisers LLC purchased a new position in Pacific Biosciences of California in the fourth quarter worth $45,000.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Scotiabank cut their price objective on shares of Pacific Biosciences of California from $6.00 to $2.00 and set a "sector outperform" rating for the company in a report on Tuesday, March 25th. StockNews.com upgraded Pacific Biosciences of California to a "sell" rating in a research note on Tuesday, February 25th. The Goldman Sachs Group reduced their target price on Pacific Biosciences of California from $1.75 to $1.50 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Stephens restated an "overweight" rating and issued a $2.50 price objective on shares of Pacific Biosciences of California in a research report on Friday, February 14th. Finally, Piper Sandler restated a "neutral" rating and set a $2.00 target price (down from $2.50) on shares of Pacific Biosciences of California in a research report on Thursday, February 20th. One analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Pacific Biosciences of California currently has a consensus rating of "Hold" and a consensus target price of $2.45.

Pacific Biosciences of California Trading Up 1.8 %

Pacific Biosciences of California stock traded up $0.02 during trading hours on Friday, reaching $1.13. The stock had a trading volume of 5,908,510 shares, compared to its average volume of 9,716,307. The stock has a market cap of $339.05 million, a PE ratio of -0.69 and a beta of 2.04. The company has a fifty day simple moving average of $1.26 and a 200-day simple moving average of $1.66. The company has a debt-to-equity ratio of 1.97, a current ratio of 9.74 and a quick ratio of 8.64. Pacific Biosciences of California, Inc. has a 52 week low of $1.06 and a 52 week high of $2.72.

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The biotechnology company reported ($0.20) EPS for the quarter, meeting analysts' consensus estimates of ($0.20). Pacific Biosciences of California had a negative return on equity of 42.89% and a negative net margin of 200.40%. The business had revenue of $39.22 million during the quarter, compared to analyst estimates of $39.20 million. During the same quarter in the prior year, the company posted ($0.27) EPS. Analysts forecast that Pacific Biosciences of California, Inc. will post -0.72 EPS for the current fiscal year.

Insider Buying and Selling

In other Pacific Biosciences of California news, insider Michele Farmer sold 24,349 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $1.88, for a total value of $45,776.12. Following the completion of the sale, the insider now owns 187,592 shares in the company, valued at approximately $352,672.96. This represents a 11.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 2.40% of the stock is currently owned by corporate insiders.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.